KRAS and neoplasm: Although they use sensitive assay with a detection limit of at least 0.5% V600E tumor cells, the copy number of mutant versus wild-type alleles in their cells, cross-reactivity with non-target BRAF mutations, and KRAS mutation status were not clearly described.